Log in to search using one of your social media accounts:

 

His Mexico City Apartment Block Was Built Only Months Ago. So Why Did It Collapse So Easily?
In April, Luis Resendiz was ecstatic to move into his brand new apartment in a sleek block with solar panels in a middle class neighborhood of Mexico City. The 35-year-old photographer had paid 2.2 million pesos ($125,000) for the property, a significant amount in a country with a daily minimum wage of $4. But through hard work and with the help of a hefty bank loan, he made what he thought was a worthwhile life investment. Then on Tuesday, he heard via Whatsapp that his home had been flattened by the factor 7.1 earthquake that killed at least 295 people on Sept. 19. His life was saved by the fact he was away working, but ...
Source: TIME.com: Top Science and Health Stories - September 23, 2017 Category: Consumer Health News Authors: Ioan Grillo / Mexico City Tags: Uncategorized Mexico Source Type: news

Key House Appropriator Backs NSF Physical Sciences Boost
During floor debate on the House ’s omnibus spending bill for fiscal year 2018, Commerce, Justice, and Science Appropriations Subcommittee Chair John Culberson (R-TX) supported a successful amendment by Science Committee Chair Lamar Smith (R-TX) to shift $30.2 million to physical and biological sciences research at the National S cience Foundation from other agency activities. Although a small amount, Culberson’s support for the amendment indicates he is sympathetic to Smith’s broader push to prioritize the physical sciences. (Source: FYI: The AIP Bulletin of Science Policy News)
Source: FYI: The AIP Bulletin of Science Policy News - September 20, 2017 Category: Physics Authors: awolfe Source Type: news

Sympathetic ophthalmia following accidental burn with hot water involving the other eye - Rahman Z, Ali S, Dutta Majumder P.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - September 20, 2017 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Phrixus to study P-188 NF in Phase II trial to treat DMD
US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news

Santhera shares plummet after negative CHMP opinion
ZURICH (Reuters) - Swiss drugmaker Santhera's shares plunged nearly 60 percent in early trading on Friday, after a European panel recommended against approving one of its drugs to be used in patients with Duchenne muscular dystrophy (DMD). (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

University of Minnesota researchers replicate FSH muscular dystrophy in mice
(University of Minnesota) A new study published in the journal Nature Communications describes a breakthrough in research related to facioscapulohumeral muscular dystrophy (FSHD). The debilitating genetic disease -- which has no approved treatment -- affects an estimated 38,000 Americans and causes muscle degeneration. Scientists inserted into mice a gene called DUX4, which is believed to cause FSHD in humans. When they activated the gene in mice skeletal muscle cells, the animals developed a muscular dystrophy with key features of FSHD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 15, 2017 Category: International Medicine & Public Health Source Type: news

Conservatives have ‘lost the argument’ on public sector pay, says UNISON
Commenting on the news that the DUP (Democratic Unionist Party) could support a Labour motion calling for an end to the public sector pay cap in the NHS, UNISON general secretary Dave Prentis said: “This is even more evidence that the Conservatives have lost the argument on public sector pay. Ministers must know they’re in the wrong when even their quasi-coalition partners in the DUP have turned against them, and backed pay rises for NHS workers. “UNISON’s campaigning on this vital issue has really begun to pay off. Across the country teaching assistants, paramedics, social workers and police suppor...
Source: UNISON Health care news - September 13, 2017 Category: UK Health Authors: Charlotte Jeffs Tags: News Press release dave prentis government public sector pay public services Source Type: news

This Is How Telethons Became a Fundraising Tradition
When Hollywood bands together for Hand In Hand: A Benefit For Hurricane Harvey Relief on Tuesday night, the entertainers who show up will be participating in a long-running tradition of lending star power to important causes via televised fundraisers. While the comedian Jerry Lewis became the biggest celebrity telethon-er when he started hosting fundraisers for the Muscular Dystrophy Association in the ’50s he wasn’t the first to do one. Comedian Milton Berle is credited with hosting the first telethon, which NBC broadcasted from 12 p.m. on April 9, 1949, to 3:55 a.m. on April 10th. The 16-hour telecast raised ...
Source: TIME.com: Top Science and Health Stories - September 12, 2017 Category: Consumer Health News Authors: Olivia B. Waxman Tags: Uncategorized health photography Television Source Type: news

Migraine Patients Need to Hear: It ’s Physiologic and Treatable
From PAINWeek 2017: Reflex vasodilation is out, neurobiologic dysfunction is in as explanation for migraine etiology. (Source: ConsultantLive)
Source: ConsultantLive - September 7, 2017 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Pain Migraine Source Type: news

​Why Sarepta’s latest trial data may presage another FDA controversy
One year after scoring one of the most controversial FDA approvals in recent history, Cambridge-based Sarepta Therapeutics may again find itself at the center of a debate over the agency ’s standards with a new experimental drug. Sarepta (Nasdaq: SRPT) on Wednesday unveiled data from a small, early-stage trial of one of its potential treatments for Duchenne muscular dystrophy, a genetic disorder in which the absence of a protein called dystrophin causes progressive muscle weaknes s. According to… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 6, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

​Why Sarepta’s latest trial data may presage another FDA controversy
One year after scoring one of the most controversial FDA approvals in recent history, Cambridge-based Sarepta Therapeutics may again find itself at the center of a debate over the agency ’s standards with a new experimental drug. Sarepta (Nasdaq: SRPT) on Wednesday unveiled data from a small, early-stage trial of one of its potential treatments for Duchenne muscular dystrophy, a genetic disorder in which the absence of a protein called dystrophin causes progressive muscle weaknes s. According to… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 6, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Paroxysmal sympathetic hyperactivity: the storm after acute brain injury - Meyfroidt G, Baguley IJ, Menon DK.
A substantial minority of patients who survive an acquired brain injury develop a state of sympathetic hyperactivity that can persist for weeks or months, consisting of periodic episodes of increased heart rate and blood pressure, sweating, hyperthermia, a... (Source: SafetyLit)
Source: SafetyLit - August 24, 2017 Category: International Medicine & Public Health Tags: TBI Source Type: news

New understanding of how muscles work
(McGill University) Muscle malfunctions may be as simple as a slight strain after exercise or as serious as heart failure and muscular dystrophy. A new technique developed at McGill University now makes it possible to look much more closely at how sarcomeres, the basic building blocks within all skeletal and cardiac muscles, work together. It's a discovery that should advance research into a wide range of muscle malfunctions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 23, 2017 Category: International Medicine & Public Health Source Type: news

The King of Comedy, Jerry Lewis Dies at 91 - AARP
5 hours ago ... Comedian Jerry Lewis, known for his unique brand of comedy and his work with the Muscular Dystrophy Association, passed away in Las  ... (Source: AARP.org News)
Source: AARP.org News - August 22, 2017 Category: American Health Source Type: news

Duchenne Action Month Needs YOU!
This September, we are asking you, our community, to participate in Duchenne Action Month in order to create awareness, raise money, and make an impact in the fight to #endDuchenne. Check out 10 simple and powerful actions you can take to make an impact this September: www.parentprojectmd.org/actionmonth (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 22, 2017 Category: Neurology Source Type: news

[Webinar] Gene Therapy for Duchenne - August 2017
Last week, PPMD hosted a webinar focused on understanding the different therapies that are being developed that are commonly referred to as gene therapy, including micro-dystrophin and CRISPR/Cas9, how are they similar and different, and what are the challenges and limitations for each of them. If you missed it, the recording of the webinar is now available! COMING SOON: This fall PPMD will be hosting additional webinars with companies and institutions who are developing gene therapies and/or CRISPR/Cas9 for Duchenne. Stay tuned for more details! (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 22, 2017 Category: Neurology Source Type: news

How You Can Participate in the Ataluren Ad Comm
The FDA has announced the scheduling of a September 28th Advisory Committee Meeting for PTC ’s therapy ataluren. Whether submitting written testimony and/or attending the Ad Comm in person, there are multiple ways for Duchenne community members in the U.S. and abroad to have an impact and share your personal experience with the Advisory Committee reviewing this product. Visit our blog to learn how you can participate. (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 22, 2017 Category: Neurology Source Type: news

Comic and Telethon Host Jerry Lewis Dies At 91
The legendary actor and comedian helped raise more than $2 billion for muscular dystrophy. (Source: WebMD Health)
Source: WebMD Health - August 21, 2017 Category: Consumer Health News Source Type: news

PPMD's Bone Health Workshop Published
Bone health has long been a confusing and often neglected aspect of Duchenne care. There is very little knowledge of underlying bone health in Duchenne, which is further complicated by the possible effects of glucocorticoids on both bone development and bone density/strength. We applaud the incredible work of this group of experts who participated in PPMD's Bone Health Workshop, and hope that, with increased awareness, further work to prevent osteoporosis and enhance bone health in people living with Duchenne will continue. (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 18, 2017 Category: Neurology Source Type: news

PPMD's Every Single [One] Tour: Charleston, WV
Registration for the next stop on PPMD's Every Single [One] Tour is now open! Combining each of the pillars that make up PPMD's mission -- To #EndDuchenne -- the Every Single [One] Tour brings free day-long meetings featuring updates on research, advocacy, and care to the Duchenne community across the country. We hope to see you in Charleston, WV on September 9! (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 17, 2017 Category: Neurology Source Type: news

How Will Animals React to the Solar Eclipse? Depends on How Smart They Are
Crickets will chirp, cows will march back to their barns and swarms of once-busy honeybees will fly hurriedly home to their hives when a total solar eclipse sweeps across the U.S. next week. The sudden darkness that comes when the moon momentarily blocks the entire sun on Aug. 21 will cause some animals to experience a range of reactions, including confusion, fright and excitement, experts say. While animals like insects and bats behave as if nighttime has simply come early, other more intelligent animals — chimpanzees, dolphins and llamas — appear to stop and stare at the sky, showing signs of understanding a ...
Source: TIME.com: Top Science and Health Stories - August 17, 2017 Category: Consumer Health News Authors: Melissa Chan Tags: Uncategorized animals eclipse onetime space space 2017 Source Type: news

Infant parasympathetic and sympathetic activity during baseline, stress and recovery: interactions with prenatal adversity predict physical aggression in toddlerhood - Suurland J, van der Heijden KB, Huijbregts SCJ, Van Goozen SHM, Swaab H.
Exposure to prenatal adversity is associated with aggression later in life. Individual differences in autonomic nervous system (ANS) functioning, specifically nonreciprocal activation of the parasympathetic (PNS) and sympathetic (SNS) nervous systems, incr... (Source: SafetyLit)
Source: SafetyLit - August 9, 2017 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Understanding Clinical Trials in Duchenne
Did you know that there are over 50 clinical trials going on in the US focused on Duchenne& Becker? While having so many clinical trials is exciting, it can also be overwhelming when you are trying to make a decision about if you want to be in a study and if so, which study is the best fit for you and your family. Learn more about the current clinical trial landscape& the PPMD resources that can help you explore clinical trial options. (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 7, 2017 Category: Neurology Source Type: news

View the Eclipse Safely with These Expert Tips
Treatment TermsEye careRetinal disease Author Sarah Avery Overview As excitement about the Aug. 21 solar eclipse builds, it ’s important to know how to safely view the event and understand how even everyday exposure to the sun can damage vision. Duke retina specialist and ophthalmologist Lejla Vajzovic from the Duke Eye Center shares her insights. Content Blocks Header How does the sun damage eyes? ContentAnytime you stare at the sun, you risk damaging your eyes, because the sun causes a physical burn at the back of the eye. The retina is essentially an extension of the brain, and it ’s made up of very ...
Source: dukehealth.org: Duke Health News - August 4, 2017 Category: Consumer Health News Authors: dg62 at duke.edu Source Type: news

Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 Million
Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis SAN DIEGO and REHOVOT, Israel, Aug. 2, 2017 -- (Healthcare Sales & Marketing Network) -- Sevion Therapeutics, Inc. (OTCQB: SVON) a... Biopharmaceuticals, Venture Capital Eloxx Pharmaceuticals, Cystic Fibrosis, Duchene Muscular Dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 2, 2017 Category: Pharmaceuticals Source Type: news

Sympathetic under-arousal and externalizing behavior problems in children with autism spectrum disorder - Baker JK, Fenning RM, Erath SA, Baucom BR, Moffitt J, Howland MA.
Children with autism spectrum disorder (ASD) commonly exhibit co-occurring externalizing behavior problems, which can impede learning opportunities and contribute significantly to caregiver stress. Substantial theory and research has linked under-arousal o... (Source: SafetyLit)
Source: SafetyLit - July 31, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Exposure to intimate partner violence in utero and infant internalizing behaviors: moderation by salivary cortisol-alpha amylase asymmetry - Martinez-Torteya C, Bogat GA, Lonstein JS, Granger DA, Levendosky AA.
Guided by the main tenets of contemporary models of the developmental origins of health and disease, this study evaluated whether individual differences in reactivity of the hypothalamic-pituitary-adrenal (HPA) axis and Sympathetic Nervous System (SNS) mod... (Source: SafetyLit)
Source: SafetyLit - July 25, 2017 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Gene therapy: Microdystrophin restores muscle strength in Duchenne muscular dystrophy
(AFM-T é l é thon) Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy. Indeed, after injecting microdystrophin (a 'shortened' version of the dystrophin gene) via a drug vector, the researchers managed to restore muscle strength and stabilise the clinical symptoms in dogs naturally affected by Duchenne muscular dystrophy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2017 Category: International Medicine & Public Health Source Type: news

Interaction between prenatal risk and infant parasympathetic and sympathetic stress reactivity predicts early aggression - Suurland J, van der Heijden KB, Huijbregts SCJ, Van Goozen SHM, Swaab H.
Nonreciprocal action of the parasympathetic (PNS) and sympathetic (SNS) nervous systems, increases susceptibility to emotional and behavioral problems in children exposed to adversity. Little is known about the PNS and SNS in interaction with early adversi... (Source: SafetyLit)
Source: SafetyLit - July 22, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Sarepta hikes full-year sales estimate for Duchenne drug
Sarepta Therapeutics reported Wednesday that sales of its Duchenne muscular dystrophy drug have picked up momentum since the FDA's controversial approval of the treatment last year. Cambridge-based Sarepta (Nasdaq: SRPT) said that the drug, Exondys 51, had generated $35 million in sales in the second quarter of 2017. That easily exceeded the consensus estimate of analysts, which was around $22 million. Sarepta also raised its guidance for total revenue in 2017, from more tha n $95 million to between… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 19, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Sarepta hikes full-year sales estimate for Duchenne drug
Sarepta Therapeutics reported Wednesday that sales of its Duchenne muscular dystrophy drug have picked up momentum since the FDA's controversial approval of the treatment last year. Cambridge-based Sarepta (Nasdaq: SRPT) said that the drug, Exondys 51, had generated $35 million in sales in the second quarter of 2017. That easily exceeded the consensus estimate of analysts, which was around $22 million. Sarepta also raised its guidance for total revenue in 2017, from more tha n $95 million to between… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 19, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

​BioMarin snags cash as Sarepta skips Duchenne patent battle
Sarepta Therapeutics Inc. agreed to pay $35 million plus royalties and potential milestones to BioMarin Pharmaceutical Inc. to resolve a dispute over patents on its Duchenne muscular dystrophy drug. Sarepta (NASDAQ: SRPT) said Tuesday it had reached an agreement to license the intellectual property of San Rafael-based BioMarin (NASDAQ: BMRN), which had challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51 as well as other so-called “exon-skipping” treatments. Tre nding:… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 18, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
Designation Covers Broad Treatment of Duchenne Muscular Dystrophy (DMD) LOS ANGELES, July 18, 2017 -- (Healthcare Sales & Marketing Network) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duch... Biopharmaceuticals, FDA Capricor Therapeutics, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news

​Sarepta skips over a Duchenne patent battle with $35M settlement
Cambridge-based Sarepta Therapeutics has agreed to pay $35 million plus royalties and potential milestones to a California biotech to resolve a dispute over patents on its Duchenne muscular dystrophy drug. Sarepta (Nasdaq: SRPT) said Tuesday that it had reached an agreement to license the intellectual property of San Rafael-based BioMarin Pharmaceutical (Nasdaq: BMRN). BioMarin had previously challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51, as well as other so-called… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 18, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Mallinckrodt wins orphan drug status for long-acting muscular dystrophy therapy
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that the FDA granted orphan drug status to its long-acting cosyntropin acetate formulation, MNK-1411, for the treatment of Duchenne muscular dystrophy. In August last year, the FDA approved the company’s request to fast track its investigational new drug application for the therapy. Get the full story at our sister site, Drug Delivery Business News. The post Mallinckrodt wins orphan drug status for long-acting muscular dystrophy therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Pharmaceuticals Wall Street Beat Mallinckrodt Source Type: news

To hell with sympathetic sexism. ‘Busy mums’ don’t need your patronising help | Sian Townson
We have learned to think critically about obviously biased statements – but against prejudice dressed up as kindness, we are more defenceless• Sian Townson is a lecturer in engineeringSometimes a rule is merely implied by its exceptions – that’s what the exception that proves the rule actually means. “No swimming outside the flags” tells you it’s OK to swim between the flags. “Closed Sundays” means “Open Monday to Saturday”.ARoyal Society campaign telling you that “women can be scientists, engineers and mathematicians too” tells you that most of t...
Source: Guardian Unlimited Science - July 13, 2017 Category: Science Authors: Sian Townson Tags: Women Gender Science World news UK news Source Type: news

Tiny cellular antennae key to fat formation in muscle
(University of California - San Francisco) Like it or not, as we age, our muscle cells are slowly exchanged, one by one, for fat cells. This process quickens when we injure a muscle, and an extreme form of this process is also seen in muscle-wasting diseases such as Duchenne muscular dystrophy (DMD). Now, scientists at UC San Francisco have shown that cellular antennae called cilia, found on fat-forming cells interspersed in muscle, play a key role in this muscle-to-fat transformation. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 13, 2017 Category: International Medicine & Public Health Source Type: news

How FDA plans to help consumers capitalize on advances in science
By: Scott Gottlieb, M.D. We’re at a point in science where new medical technologies hold out the promise of better treatments for a widening number of vexing conditions. Over the last few decades, science has enabled fundamental advances in our understanding of the genetic and protein bases of human disease. These developments are already being translated into new medicines. In more cases, these treatments target the underlying mechanisms that drive different diseases. These advances hold out the promise of arresting and even curing a growing number of diseases. To build upon such opportunities, FDA will soon unveil ...
Source: Mass Device - July 11, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog FDA Voice Source Type: news

UF Health researchers find genetic factors that cause muscle weakness, wasting disorder
(University of Florida) For years, the underlying process that causes a debilitating muscle disorder in infants and young children has been largely unknown. Now, a group that includes University of Florida Health genetics researchers has identified the fundamental mechanism that causes congenital myotonic dystrophy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2017 Category: International Medicine & Public Health Source Type: news

Sarepta names former Allergan executive as new CEO
Sarepta Therapeutics, the Cambridge biotech that won approval last year for the first-ever Duchenne muscular dystrophy drug, said Wednesday that it had appointed former Allergan executive Douglas Ingram as its new CEO. Sarepta (Nasdaq: SRPT) had been searching for a new CEO after Ed Kaye announced in April that he planned to step down. Ingram served as president of Allergan until the company was acquired by Actavis in 2015. More recently, he was CEO of Chase Pharmaceuticals, a California biotech… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 28, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

Sarepta names former Allergan executive as new CEO
Sarepta Therapeutics, the Cambridge biotech that won approval last year for the first-ever Duchenne muscular dystrophy drug, said Wednesday that it had appointed former Allergan executive Douglas Ingram as its new CEO. Sarepta (Nasdaq: SRPT) had been searching for a new CEO after Ed Kaye announced in April that he planned to step down. Ingram served as president of Allergan until the company was acquired by Actavis in 2015. More recently, he was CEO of Chase Pharmaceuticals, a California biotech… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 28, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Optimal Beta-blockers May Avert Post-ICD Shock HF Decompensation Optimal Beta-blockers May Avert Post-ICD Shock HF Decompensation
A spike in sympathetic activation after shocks, whether appropriate or not, may raise the risk of heart-failure decompensation within a few months, but maybe less so if beta-blockers are on board.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Insurers Battle Families Over Costly Drug for Fatal Disease
The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof. (Source: NYT Health)
Source: NYT Health - June 22, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Health Insurance and Managed Care Muscular Dystrophy Aetna Inc Food and Drug Administration Sarepta Therapeutics Inc. Prices (Fares, Fees and Rates) Source Type: news

14 Years Old. Losing Muscle Every Day.
Nicolas is 14 and has Duchenne muscular dystrophy, which is robbing him of his muscles — and his life. A new and expensive drug may help, but can he get it? (Source: NYT Health)
Source: NYT Health - June 22, 2017 Category: Consumer Health News Tags: Muscular Dystrophy Food and Drug Administration Drugs (Pharmaceuticals) Source Type: news

Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation
Duchenne muscular dystrophy (DMD) is a rare disease that causes the progressive loss of motor abilities such as walking. Standard treatment includes physiotherapy. No trial has evaluated whether or not adding aquatic therapy (AT) to land-based therapy (LBT) exercises helps to keep muscles strong and children independent. To assess the feasibility of recruiting boys with DMD to a randomised trial evaluating AT (primary objective) and to collect data from them; to assess how, and how well, the intervention and trial procedures work. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 21, 2017 Category: Consumer Health News Source Type: news

Sarepta Therapeutics and Genethon announce gene therapy research collaboration for Duchenne muscula
(AFM-T é l é thon) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), and Genethon have signed a gene therapy research collaboration to jointly develop treatments for Duchenne muscular dystrophy (DMD). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 21, 2017 Category: Biology Source Type: news

How Smart People Handle Toxic People
Toxic people defy logic. Some are blissfully unaware of the negative impact that they have on those around them, and others seem to derive satisfaction from creating chaos and pushing other people’s buttons. Either way, they create unnecessary complexity, strife, and worst of all stress. Studies have long shown that stress can have a lasting, negative impact on the brain. Exposure to even a few days of stress compromises the effectiveness of neurons in the hippocampus—an important brain area responsible for reasoning and memory. Weeks of stress cause reversible damage to neuronal dendrites (the small “arm...
Source: Healthy Living - The Huffington Post - June 18, 2017 Category: Consumer Health News Source Type: news

I've Broken This Mortifying Office Taboo — And I Bet I'm Not Alone
Here’s an awkward piece of personal trivia: I’ve cried at every job I’ve had. When I was navigating an endless first-job search and grabbed a coffee with my internship supervisor, I soaked an unsuspecting chocolate croissant in tides of frustrated tears. Then there was that afternoon I had a low-key cubicle weep after jamming a printer with the universe’s stickiest mailing labels and was dressed down by the angry office manager. Even in my current role, I’ve furtively re-applied a few swipes of waterproof mascara on days when the dizzying pace of digital media catches me off guard. And each ti...
Source: Healthy Living - The Huffington Post - June 15, 2017 Category: Consumer Health News Source Type: news

Muscle growth finding may assist with cancer treatment
(Monash University) Monash University's Biomedicine Discovery Institute (BDI) researchers have collaboratively developed a therapeutic approach that dramatically promotes the growth of muscle mass, which could potentially prevent muscle wasting in diseases including muscular dystrophy and cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2017 Category: Cancer & Oncology Source Type: news

Researchers aim to repurpose former experimental cancer therapy to treat muscular dystrophy
Duchenne muscular dystrophy is caused by a faulty gene that leads to progressive muscle weakness. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 13, 2017 Category: American Health Source Type: news